<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224445</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-164-0115</org_study_id>
    <nct_id>NCT00224445</nct_id>
  </id_info>
  <brief_title>Boosted Atazanavir and Truvada Given Once-Daily - BATON Study</brief_title>
  <official_title>Boosted Atazanavir and Truvada Given Once-Daily (BATON Study): A Phase 4 Study of Safety, Efficacy &amp; Adherence in HIV Infected, Antiretroviral Naïve Subjects Treated With a Simple Once-Daily Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of a simple, once-daily antiretroviral (ARV) regimen&#xD;
      consisting of a fixed-dose combination tablet containing Truvada combined with atazanavir&#xD;
      boosted with ritonavir in treatment naive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety and efficacy (viral load suppression and cluster of differentiation 4&#xD;
      [CD4] changes) of a simple, once-daily (QD) antiretroviral (ARV) regimen consisting of a&#xD;
      fixed-dose combination tablet containing Truvada combined with the protease inhibitor&#xD;
      atazanavir (ATV) boosted with ritonavir (ATV/r).&#xD;
&#xD;
      To evaluate fasting glucose, insulin, C peptide and lipid panel (total cholesterol, high and&#xD;
      low density lipoprotein cholesterol (HDL, LDL), and serum triglycerides) in subjects&#xD;
      receiving Truvada and boosted atazanavir.&#xD;
&#xD;
      To evaluate adherence to a QD ARV regimen of Truvada and boosted atazanavir.&#xD;
&#xD;
      To evaluate steady-state plasma pharmacokinetics (PK) of Truvada and atazanavir in study&#xD;
      subjects receiving Truvada and boosted atazanavir.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety/efficacy (viral load suppression and CD4 changes) of a once-daily (QD) antiretroviral (ARV) regimen consisting of a fixed-dose combination tablet containing Truvada.</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate fasting glucose, insulin, C peptide and lipid panel (total cholesterol, high and low density lipoprotein cholesterol (HDL, LDL), and serum triglycerides) in subjects receiving Truvada and boosted atazanavir.</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate adherence to a QD ARV regimen of Truvada and boosted atazanavir.</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate steady-state plasma PK of Truvada &amp; atazanavir in study subjects receiving Truvada and boosted atazanavir.</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Truvada + Ritonavir-boosted Atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants received Truvada plus ritonavir-boosted atazanavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)</description>
    <arm_group_label>Truvada + Ritonavir-boosted Atazanavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD</description>
    <arm_group_label>Truvada + Ritonavir-boosted Atazanavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100 mg capsule administered orally QD</description>
    <arm_group_label>Truvada + Ritonavir-boosted Atazanavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (greater than or equal to 18 years) male or non-pregnant female HIV 1- infected&#xD;
             subjects regardless of race or ethnicity.&#xD;
&#xD;
          -  Antiretroviral treatment-naïve.&#xD;
&#xD;
          -  Plasma HIV 1 RNA greater than 1000 copies/mL (Roche Amplicor HIV 1 Monitor Test&#xD;
             Version 1.5 Ultrasensitive method, with a reflex to Standard for results greater than&#xD;
             75,000 and dilution for results greater than 750,000). There are no CD4 criteria for&#xD;
             study inclusion.&#xD;
&#xD;
          -  Adequate renal function defined as a calculated creatinine clearance (CLCr) greater&#xD;
             than or equal to 50 mL/min according to the Cockcroft-Gault formula:&#xD;
&#xD;
          -  Male: (140 - age in years) x (wt in kg) divided by 72 x (serum creatinine in mg/dL) =&#xD;
             CLCr (mL/min.&#xD;
&#xD;
          -  Female: (140 - age in years) x (wt in kg) divided by 72 x (serum creatinine in mg/dL)&#xD;
             x 0.85 = CLCr (mL/min).&#xD;
&#xD;
          -  Negative serum pregnancy test (females of childbearing potential only).&#xD;
&#xD;
          -  Males and females (of childbearing potential, i.e. less than 2 years post-menopausal)&#xD;
             must agree to avoid pregnancy by sexual abstinence, or utilization of a highly&#xD;
             effective method of birth control throughout the study period and for 30 days&#xD;
             following discontinuation of study drug.&#xD;
&#xD;
          -  Life expectancy greater than or equal to 1 year.&#xD;
&#xD;
          -  Subjects should be available for follow up for a period of at least 48 weeks.&#xD;
&#xD;
          -  The ability to understand and sign a written informed consent form, which must be&#xD;
             obtained prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior antiretroviral treatment.&#xD;
&#xD;
          -  Screening ALT greater than 5 x the upper limit of the normal range (ULN).&#xD;
&#xD;
          -  Proven or suspected acute hepatitis in the 30 days prior to study entry. Subjects with&#xD;
             chronic hepatitis are eligible provided that their liver transaminases (ALT) are less&#xD;
             than 5 x ULN.&#xD;
&#xD;
          -  A new AIDS defining condition diagnosed (with the exception of CD4 criteria) within 30&#xD;
             days of baseline.&#xD;
&#xD;
          -  Previous therapy with agents with systemic myelosuppressive, pancreatoxic, hepatotoxic&#xD;
             or cytotoxic potential within 3 months of study start or the expected need for such&#xD;
             therapy at the time of enrollment.&#xD;
&#xD;
          -  Presence of cardiomyopathy.&#xD;
&#xD;
          -  Heart rate less than 40 bpm.&#xD;
&#xD;
          -  Clinical symptoms potentially related to heart block (syncope, palpitations,&#xD;
             unexplained dizziness)&#xD;
&#xD;
          -  Known conduction disease.&#xD;
&#xD;
          -  Third degree heart block.&#xD;
&#xD;
          -  Clinically significant laboratory values that would preclude prescribing&#xD;
             antiretroviral therapy, in the opinion of the investigator.&#xD;
&#xD;
          -  Receiving ongoing therapy with any of the following (administration of any of the&#xD;
             following medications must be discontinued at least 30 days prior to the Baseline&#xD;
             visit and for the duration of the study period):&#xD;
&#xD;
               -  Nephrotoxic agents (aminoglycoside antibiotics, amphotericin B, cidofovir,&#xD;
                  cisplatin, foscarnet, IV pentamidine, other agents with significant nephrotoxic&#xD;
                  potential):&#xD;
&#xD;
               -  Adefovir dipivoxil&#xD;
&#xD;
               -  Probenecid&#xD;
&#xD;
               -  Systemic chemotherapeutic agents (i.e., cancer treatment medications)&#xD;
&#xD;
               -  Systemic corticosteroids&#xD;
&#xD;
               -  Interleukin 2 (IL 2)&#xD;
&#xD;
               -  Investigational agents (except upon approval by Gilead).&#xD;
&#xD;
          -  Drugs that are contraindicated with atazanavir and/or ritonavir including:&#xD;
&#xD;
               -  midazolam&#xD;
&#xD;
               -  triazolam&#xD;
&#xD;
               -  ergot alkaloids&#xD;
&#xD;
               -  pimozide&#xD;
&#xD;
               -  proton-pump inhibitors&#xD;
&#xD;
               -  H2 blockers&#xD;
&#xD;
               -  lovastatin&#xD;
&#xD;
               -  simvastatin&#xD;
&#xD;
               -  diltiazem&#xD;
&#xD;
               -  amiodarone&#xD;
&#xD;
               -  bepridil&#xD;
&#xD;
               -  flecainide&#xD;
&#xD;
               -  propafenone&#xD;
&#xD;
               -  quinidine&#xD;
&#xD;
               -  St. John's Wort&#xD;
&#xD;
               -  rifampin&#xD;
&#xD;
               -  irinotecan&#xD;
&#xD;
          -  Pregnant or lactating subjects.&#xD;
&#xD;
          -  Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting&#xD;
             which may confer an inability to receive an orally administered medication.&#xD;
&#xD;
          -  Current alcohol or substance abuse judged by the investigator to potentially interfere&#xD;
             with subject adherence.&#xD;
&#xD;
          -  Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.&#xD;
             Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received&#xD;
             any systemic therapy for KS within 30 days of baseline and are not anticipated to&#xD;
             require systemic therapy during the study.&#xD;
&#xD;
          -  Active, serious infections (other than HIV 1 infection) requiring parenteral&#xD;
             antimicrobial therapy within 15 days prior to screening.&#xD;
&#xD;
          -  Prior history of significant renal or bone disease.&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             investigator, would make the subject unsuitable for the study or unable to comply with&#xD;
             the dosing requirements.&#xD;
&#xD;
          -  Current imprisonment or involuntary incarceration in a medical facility for&#xD;
             psychiatric or physical (e.g., infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Flaherty</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gilead Sciences, Inc.</name>
      <address>
        <city>Foster City</city>
        <state>California</state>
        <zip>94403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.gilead.com</url>
    <description>Gilead Website</description>
  </link>
  <link>
    <url>http://www.truvada.com</url>
    <description>Truvada Website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

